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ABSTRACT 
Introduction: Diagnostic delays of ovarian cancer, has been attributed to the lack of a 
reliable and cost-effective screening test and presumption that ovarian cancer is asymptomatic 
in the early stages. To investigate presenting symptoms of ovarian cancer and compare with 
symptoms of other abdominal-pelvic cancers 
Methods: We reviewed the medical records of all women with abdominal-pelvic cancers 
between March, 2003 and March, 2005 in Shiraz medical centers to compare, presenting 
symptoms of ovarian cancer and other abdominal-pelvic cancers. 
Results: Of 168 women with a diagnosis of abdominal-pelvic cancers, ovarian cancer was 
diagnosed for 22 women. (Stage I: 0, Stage II: 2, Stage III: 10, Stage IV: 7 and 3 patients 
without staging.) The mean age of patients with ovarian cancer was 51/6.The sensation of 
abdominal mass was more common in women with ovarian cancer than other abdominal-
pelvic cancers (P=0.00l). Constipation was documented in the patients with colon cancer 
more than women with ovarian cancer (P=0.012), whereas urinary symptoms were more 
common in patients with ovarian cancer (P=0.004).Although the women with bladder cancer 
complained from urinary problems more than who had ovarian cancer (P=0.00l), but 
defecation problems and abdominal pain were more detected in patients with ovarian cancer 
(p=0.05). 
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Conclusion: The most common cases of ovarian cancer present in the end stage that usually 
have poor prognosis. It can be associated to both patient and healthcare factors. This cancer is 
associated with many symptoms, but few symptoms are related to reproductive system. 
Sensation of abdominal mass, abdominal pain and urinary and defecation problems are the 
symptoms that can be associated with this cancer. 
Key words: Presenting Symptoms, Ovarian Cancer, and Abdominal-Pelvic Cancers. 
 
INTRODUCTION 
Ovarian cancer is the fifth most common cause of cancer-related deaths in US women after 
lung, breast, colon, and pancreatic cancer (1-4). Most women 60%-75% (3-5) have stage III 
or IV tumors at diagnosis, with 5-year survival rates of 30% or less(2,5-6). Despite aggressive 
surgery and chemotherapy, the prognosis for these women is poor, with a 5-year survival rate 
of less than 30%. This outcome is due, in large part, to the lack of effective prevention and 
early detection strategies. Diagnosis of ovarian cancer in early stages is very important and 
can improve the prognosis of the patients. The advanced stage of ovarian cancer at diagnosis 
has been attributed to 2 factors: the lack of a sufficiently reliable and cost-effective screening 
test (7-10) and the presumption that ovarian cancer is asymptomatic in the early stages, 
resulting in diagnostic delays (11-15) Symptoms of ovarian cancer are often described as non-
specific, but in many studies suggest that women may have symptoms for weeks to months 
before the initial diagnosis of ovarian cancer(11,13,16)For most women, the initial 
documented symptoms were not specifically related to the pelvis or commonly considered 
gynecologic problems(17).The prevalence of the early non-specific symptoms among the 
patients with ovarian cancer and comparing with healthy women has been studied(20), but 
differs between these patients and other patients with abdominal-pelvic cancer has not been 
investigated. The types of symptoms present in women with different delays in diagnosis have 
not been assessed (18-19), and the convicting results of medical record and self report data 
have not been addressed. The current study investigated presenting symptoms of ovarian 
cancer and compare with symptoms of other abdominal-pelvic cancers. 
 
MATERIAL &METHODS 
Patients for this case-control study were identified at two hospitals inShiraz city, Nemazee 
and Shahid Faghihi hospital where are the maincancer centers in south of Iran, from 2003-
2005. We reviewed thepathologic reports of all women who had abdominal-pelvic 
mass.Women were eligible if their pathologic reports were a primary intraabdomen or pelvic 
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cancer. Then we found their medical chart accordingto unit numbers.We used a questionnaire 
that was designed for cancers screening inShiraz medical school to collect our data. This 
questionnaire haddemographic questions and others about chief complaint of patient andother 
clinical problems (abdominal pain, abdominal mass sensation,urinary problem, defecation 
problem and vaginal discharge or bleeding).These dichotomous (Yes/No) and contingency 
questions were followedby a question about the period between the first complaint and 
diagnosis.The questionnaires were filled according the medical records of allpatients who had 
abdominal-pelvic cancer in their pathologic reports. Ifthe medical records were not 
completed, we call the patient to interview.According to the last diagnosis, the patients were 
divided to two groups:l. The patients who had ovarian cancer as the case group (group A). 2. 
And who had each other abdominal-pelvic cancer (gastric cancer, liver and biliary 
malignancy, small bowel cancer, colon cancer, renalcarcinoma, malignancy of bladder, uterus 
cancer) as the control group(group B).The patients of group A and B were divided to two sub-
groups again asthey had each clinical symptoms or did not. So we had four groups foreach 
clinical symptom: 
A1: The patients with ovarian cancer and considered clinical symptom. 
A2: The women in case group who did not have considered clinical 
symptom. 
B1: The patients in control group who had clinical symptom that wewanted to compare. 
B2: The women in control group without considered clinical symptom.At last these groups 




Between 220 patients who had abdominal-pelvic cancer, we found 168women with 
appropriate medical records (response rate: 76.36%). A total of 22 women were with incident 
cases of ovarian cancer. The mean age of the women with ovarian cancer was 51.6 (SD: 
19.38) and the patients who had other abdominal-pelvic cancers was 57.7 (SD: 15.77) at the 
time of the first referring. 31.8% of ovarian cancers were stage IV (n=7). 45.4% of women 
with ovarian cancer were diagnosed in stage III (n=10). Only 2 patients were diagnosed in 
stage II (9%) and no cancer was found in stage I. In three patients, stage of tumor was 
notknown.  
The sensation of abdominal mass was more common in women withovarian cancer than other 
abdominal-pelvic cancers (P=0.001) (Table 1).Constipation was documented in the patients 
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with colon cancer morethan women with ovarian cancer (P=0.012), whereas urinary 
symptomswere more common in patients with ovarian cancer (P=0.004) (Figure1). 
Although the women with bladder cancer complained from urinaryproblems (hematuria, 
frequency, disuria, urgency) more than who hadovarian cancer (P=0.00l), but defecation 
problems (diarrhea andconstipation) and abdominal pain were more detected in patients 
withovarian cancer (p=0.05) (Figure 2). 
 






Ovarian Cancer Symptoms 
0.20 70% 81% Abdominal Pain 
0.001 29.2% 70% Abdominal Mass 
Sensation 
0.5 36% 31.8% Urinary Problem 
0.5 50% 52% Defecation Problem 
0.1 10.9% 22.7% Uterus Bleeding 
0.49 52% 45.5% Weight Loss  
0.51 40% 27.3% Fatigue 
  
  
Fig.1. Frequency of defecation problem between the patientswith ovarian cancer, colon 
cancer and bladder cancer 
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Fig.2. Frequency of urinary problem between the patientswith ovarian cancer, colon cancer 
and bladder cancer 
  
DISCUSSION 
Most patients in our study with ovarian cancer were diagnosed in stagesIII or IV and had 
symptoms or signs for weeks to months before ovariancancer was diagnosed. These data 
showed that options for ovarian cancer prevention and early detection are limited. Our study 
revealed that sensation of abdominal mass is more common in ovarian cancer patients in 
comparison to the other abdominal-pelvic cancers. Our findings among cases are in general 
agreement with reports based on case series that bloating, fullness, and pressure in the 
abdomen is the most prominent symptom, with pain also important, followed by problems 
with urination and constipation [20-23].For most women, the initial documented symptoms 
were not specifically related to the pelvis or commonly considered gynecologic problems. 
Barbara. P et al [23] and Nelson et al [20] have found similar results in their researches. These 
results imply that ovarian cancer should take into consideration in women with symptoms that 
are not specifically relatedto the pelvis orgynecologic problems. In other studies 
gastrointestinal symptoms, either abdominal pain or bowel changes were documentedmost 
frequently as the presenting and most common symptoms in women with ovarian cancer. 
Despite the previous studies, urinary problem was more common in patients with ovarian 
cancer [23].In this way we can suggest that all patients with sensation of abdominalmass must 
be screened for ovarian cancer. On the basis of these data and information from other studies, 
it remains unclear how we can effectively increase early diagnosis of most ovarian cancers. 
Although mass screening has the potential to improve early recognition based on rapid 
technological advances in the analysis of tumor/serum markers, it remains a challenge given 
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the rarity of ovarian cancer diagnoses in the general population and the resulting high false-
positive rates of screening tests.Our study had several limitations. As ovarian cancer is not so 
common,our sample size is small. Sometimes the medical records of patients werenot 
complete and did not contain needed information. So we had to callthe patients for interview 
but sometimes the patients were died.  
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